A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin
K. Mishima et al., A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin, P NAS US, 97(15), 2000, pp. 8484-8489
Citations number
32
Categorie Soggetti
Multidisciplinary
Journal title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
The urokinase plasminogen activator system is involved in angiogenesis and
tumor growth of malignant gliomas, which are highly neovascularized and so
may be amenable to antiangiogenic therapy. In this paper, we describe the a
ctivity of Angstrom 6, an octamer capped peptide derived from the non-recep
tor-binding region of urokinase plasminogen activator. Angstrom 6 inhibited
human microvascular endothelial cell migration but had no effect on the pr
oliferation of human microvascular endothelial cells or U87MG glioma cells
in vitro. In contrast, Angstrom 6 or cisplatin (CDDP) alone suppressed subc
utaneous tumor growth in vivo by 48% and 53%, respectively, and, more strik
ingly, the combination of Angstrom 6 plus CDDP inhibited tumor growth by 92
%. Such combination treatment also greatly reduced the volume of intracrani
al tumor xenografts and increased survival of tumor-bearing animals when co
mpared with CDDP or Angstrom 6 alone. Tumors from the combination treatment
group had significantly reduced neovascularization, suggesting a mechanism
involving Angstrom 6-mediated inhibition of endothelial cell motility, the
reby eliciting vascular sensitivity to CDDP-mediated toxicity. These data s
uggest that the combination of an angiogenesis inhibitor that targets endot
helial cells with a cytotoxic agent may be a useful therapeutic approach.